



Figure S1: Comparison of expression of serum EV-enriched miRNAs at diagnosis and after treatment in each malignant mesothelioma patient in the whole study group (a: miR-625-3p, b: miR-103a-3p, c: miR-126-3p; dark blue: increased expression, light blue: decreased expression) and in each patient with poor treatment outcome (d: miR-625-3p, e: miR-103a-3p, f: miR-126-3p; dark green: increased expression, light green: decreased expression). EV: extracellular vesicles

Table S1: Expression of serum EV-enriched miRNAs and progression-free survival (PFS) and overall survival (OS) of malignant mesothelioma patients.

| | miRNA | PFS | | | | | | OS | | | | | |
|---------------------|-------------|------|---------------|--------------|------|-------------------------|------------------|------|---------------|--------------|------|-------------------------|------------------|
| | | HR | (95% CI) | P | HR | (95% CI) _{adj} | P _{adj} | HR | (95% CI) | P | HR | (95% CI) _{adj} | P _{adj} |
| At diagnosis (N=18) | miR-625-3p | 0.33 | (0.00-340.58) | 0.755 | 1.74 | (0.00-4333.43) | 0.890 | 0.06 | (0.00-393.16) | 0.535 | 3.60 | (0.00-69206.36) | 0.799 |
| | miR-103a-3p | 0.35 | (0.01-8.61) | 0.520 | 0.26 | (0.01-7.00) | 0.421 | 0.28 | (0.01-14.32) | 0.529 | 0.13 | (0.00-7.02) | 0.319 |
| | miR-126-3p | 1.01 | (0.99-1.02) | 0.533 | 1.01 | (0.99-1.02) | 0.531 | 1.01 | (0.99-1.03) | 0.192 | 1.01 | (0.99-1.03) | 0.233 |
| Change (%)* (N=17) | miR-625-3p | 1.02 | (1.00-1.04) | 0.044 | 1.02 | (1.00-1.04) | 0.046 | 1.02 | (1.00-1.05) | 0.045 | 1.03 | (1.00-1.05) | 0.042 |
| | miR-103a-3p | 0.99 | (0.91-1.07) | 0.714 | 0.99 | (0.91-1.07) | 0.742 | 1.01 | (0.92-1.10) | 0.847 | 1.02 | (0.93-1.11) | 0.725 |
| | miR-126-3p | 1.01 | (0.96-1.07) | 0.642 | 1.02 | (0.96-1.09) | 0.482 | 1.00 | (0.93-1.08) | 0.994 | 1.03 | (0.95-1.12) | 0.458 |

adj: adjusted for C-reactive protein levels at diagnosis

*HR values are reported for a difference of 10%

CI: confidence interval; EV: extracellular vesicles; HR: hazard ratio